Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors, With Emphasis on Squamous Cell Carcinoma of the Head and Neck, Triple Negative Breast Cancer, Anaplastic Thyroid Carcinoma, and Cutaneous Squamous Cell Carcinoma

NCT04592484 is registered in ClinicalTrials.gov with Codiak BioSciences as lead sponsor.

NCT NCT04592484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04592484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors, With Emphasis on Squamous Cell Carcinoma of the Head and Neck, Triple Negative Breast Cancer, Anaplastic Thyroid Carcinoma, and Cutaneous Squamous Cell Carcinoma
Lead sponsor
Codiak BioSciences
Phase
Phase 1/2
Overall status
Completed
Start date
September 15, 2020
Completion date
December 23, 2022
Enrollment
27 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor